 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 1091 | 回復(fù): 3 | |||
| 當(dāng)前只顯示滿足指定條件的回帖，點擊這里查看本話題的所有回帖 | |||
zlwcw管理員
|
[交流]
ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 已有1人參與
|
||
|
ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 2011-10-24 20:00 -------------------------------------------------------------------------------- SHANGHAI, October 24, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE:SHP) ("ShangPharma" or the "Company"  , a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has, through its main Chinese subsidiary, Shanghai ChemPartner Co. Ltd. ("ChemPartner", acquired the assets in Charles River Laboratories International, Inc.'s ("Charles River" Shanghai research facility. As part of the transaction, ShangPharma will take over Charles River's lease for the facility, which will provide the Company with an additional 2,972 square meters (31,990 square feet) of in-vivo research facilities originally designed for GLP Tox studies, and 1,290 square meters (13,885 square feet) of lab and office space. "The acquisition of one of the best designed and constructed state-of-the-art research facilities and laboratories in China is a major step forward for ShangPharma's in-vivo pharmacology services, which we expect to be a significant revenue growth driver going forward, along with biologics; research manufacturing; and integrated discovery and development services," Michael Xin Hui, founder and Chief Executive Officer of ShangPharma, commented. "The added world-class research capacity should enable ShangPharma to become a top global player in the area of comprehensive in-vivo pharmacology services with specialized capabilities." Kevin Chen, ShangPharma's President and Chief Operating Officer, commented, "This transaction nearly triples ShangPharma's overall research model production and research capacity, positioning us to further leverage China's advantages in the area of in-vivo studies. The location of this facility within ShangPharma's main research campus is a notable strategic advantage, helping us to achieve significant operating efficiencies through consolidation with our current facilities." "This acquisition from Charles River should support accelerated growth in ShangPharma's biology, preclinical development and biologics services for the next several years," added William Dai, ShangPharma's Chief Financial Officer. "ShangPharma's strong cash position has enabled us to make this strategic investment, which we expect will provide excellent returns and maximize shareholder value." Financial terms of the deal, which is subject to customary closing conditions, were not announced. ABOUT SHANGPHARMA CORPORATION ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com. For further information, please contact: ShangPharma Ms. Lan Xie VP of Finance and Investor Relations Email: ir@shangpharma.com Brunswick Group Josh Gartner Email: shangpharma@brunswickgroup.com Phone: 86-10-5960-8600 |
回復(fù)此樓» 猜你喜歡
是不是現(xiàn)在考博都是推薦制？或者是已經(jīng)內(nèi)定了？還有通過考試招博士的學(xué)校嗎？
已經(jīng)有39人回復(fù)
-
農(nóng)產(chǎn)品中農(nóng)藥監(jiān)測的免疫傳感器的疑問
已經(jīng)有0人回復(fù)
-
藥物學(xué)論文潤色/翻譯怎么收費?
已經(jīng)有123人回復(fù)
-
納米傳感器監(jiān)測農(nóng)藥殘留的疑惑
已經(jīng)有0人回復(fù)
-
誰有人衛(wèi)版 《毒理學(xué)基礎(chǔ)》第七版書籍
已經(jīng)有0人回復(fù)
-
26有沒有老師想收做定量藥理的學(xué)生啊
已經(jīng)有3人回復(fù)
-
26考博申請 學(xué)or專
已經(jīng)有15人回復(fù)
-
292藥學(xué)調(diào)劑
已經(jīng)有1人回復(fù)
» 本主題相關(guān)價值貼推薦，對您同樣有幫助:
- 鋰電池的兩篇review(Nature and Materials Research Bulletin)
已經(jīng)有286人回復(fù)
- Tier 2 Canada Research Chair in Organic and Medicinal Chemistry 是什么職稱？
已經(jīng)有3人回復(fù)
- PhD Position in Computer Vision from Queen Mary, University of London
已經(jīng)有16人回復(fù)
- Letters in Drug Design & Discovery這個期刊怎么投？
已經(jīng)有15人回復(fù)
- PhD research scholarship in Monash University, Australia
已經(jīng)有25人回復(fù)
- 幫我看看這個“約稿”是不是騙人的？Advances in Materials Research
已經(jīng)有9人回復(fù)
- 【Share】when i fall in love with you
已經(jīng)有58人回復(fù)
- 【招聘】PhD positions in Technical University of Darmstadt, Germany
已經(jīng)有3人回復(fù)
- Environmental Science and Pollution Research
已經(jīng)有14人回復(fù)
1994yw
專家顧問
- 應(yīng)助: 8 (幼兒園)
- 金幣: 1708.3
- 散金: 105
- 帖子: 646
- 在線: 79.5小時
- 蟲號: 1242523
- 注冊: 2011-03-23
- 專業(yè): 藥物設(shè)計與藥物信息
★
小木蟲(金幣+0.5):給個紅包，謝謝回帖
小木蟲(金幣+0.5):給個紅包，謝謝回帖
|
搞錯了. i美股訊)北京時間10月24日晚消息，尚華醫(yī)藥今天表示，該公司通過旗下子公司——上海睿智化學(xué)研究有限公司公司已收購了CharlES River Laboratories International位于上海的體內(nèi)藥物（In-vivo Drug ）研究室資產(chǎn)。Charles River 是全球領(lǐng)先的研究模式及相關(guān)服務(wù)和臨床前藥物研發(fā)服務(wù)提供商。 作為交易的一部分，尚華醫(yī)藥將接手Charles River對上海研究室的租賃。這起交易完成后，尚華醫(yī)藥將提供額外2，972平方米空間用于GLP Tox研究和1，290 平方米試驗和辦公空間。 注冊于開曼群島的尚華醫(yī)藥研發(fā)服務(wù)集團是上海睿智化學(xué)研究有限公司、上海凱惠醫(yī)藥化工有限公司及上海開拓者化學(xué)研究管理有限公司的控股公司。 上海睿智化學(xué)研究有限公司成立于2003年4月，公司坐落于中國藥谷——上海市浦東新區(qū)張江高科技園區(qū)生物醫(yī)藥基地內(nèi)。公司目前主要從事為國內(nèi)外客戶提供組合化學(xué)、藥物化學(xué)、合成化學(xué)等領(lǐng)域的科研服務(wù)；化工醫(yī)藥產(chǎn)品質(zhì)量測試；醫(yī)藥生物技術(shù)引進、孵化以及成果產(chǎn)業(yè)化等業(yè)務(wù)。睿智化學(xué)擁有8500平方米左右的實驗室。實驗室中均采用世界一流的研究設(shè)備,除具有進行有機合成所必需的先進的實驗儀器設(shè)備外，還擁有核磁共振儀,液相色譜-質(zhì)譜聯(lián)用儀,分析型高效液相色譜儀,制備型高效液相色譜儀等先進測試儀器。同時，睿智化學(xué)在上海設(shè)立了中試基地，具備精細化工產(chǎn)品的中試和加工能力。 上海開拓者化學(xué)研究管理有限公司成立于2002年6月，占地12000平方米,位于上海最重要的生物醫(yī)藥研發(fā)基地——張江高科技園區(qū)。 [ Last edited by 1994yw on 2011-10-31 at 21:08 ] |
4樓2011-10-31 21:05:03
1994yw
超級版主
- 應(yīng)助: 8 (幼兒園)
- 金幣: 1708.3
- 散金: 105
- 帖子: 646
- 在線: 79.5小時
- 蟲號: 1242523
- 注冊: 2011-03-23
- 專業(yè): 藥物設(shè)計與藥物信息
2樓2011-10-30 15:01:33
zlwcw
主管區(qū)長
- 應(yīng)助: 1 (幼兒園)
- 金幣: 2021.1
- 散金: 225
- 紅花: 8
- 帖子: 1274
- 在線: 219.7小時
- 蟲號: 530429
- 注冊: 2008-03-21
- 性別: GG
- 專業(yè): 代謝性疾病藥物藥理
3樓2011-10-30 17:02:28
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 085600 295分求調(diào)劑 +15 | W55j 2026-03-30 | 18/900 |
|
|---|---|---|---|---|
|
[考研] 296求調(diào)劑 +4 | 汪��？！ 2026-03-31 | 7/350 |
|
|
|
[考研] 286分調(diào)劑 +18 | Faune 2026-03-30 | 20/1000 |
|
|
|
[考研]
 重慶大學(xué)材料與化工085600，初試370+，求求調(diào)劑建議
+3
|
shzhou_ 2026-04-01 | 3/150 |
|
|
|
[考研] 353求調(diào)劑 +4 | 拉鉤不許變 2026-04-01 | 4/200 |
|
|
|
[考研] 材料與化工（0856）304求B區(qū)調(diào)劑 +8 | 邱gl 2026-03-30 | 16/800 |
|
|
|
[考研] 294分080500材料科學(xué)與工程求調(diào)劑 +15 | 柳溪邊 2026-03-26 | 16/800 |
|
|
|
[考研] 0856初試324分求調(diào)劑 +5 | 想上學(xué)求調(diào) 2026-04-01 | 5/250 |
|
|
|
[考研] 一志愿211，335分，0856，求調(diào)劑院校和導(dǎo)師 +11 | 傾____蕭 2026-03-27 | 12/600 |
|
|
|
[考研] 材料0856 英一數(shù)二 323 求調(diào)劑 +9 | 袁sy 2026-04-01 | 9/450 |
|
|
|
[考研] 已決定調(diào)劑院校 +8 | JKSOIID 2026-03-26 | 8/400 |
|
|
|
[考研] 0856 335分 +9 | cccchenso 2026-03-29 | 9/450 |
|
|
|
[考研] 學(xué)碩274求調(diào)劑 +17 | Li李魚 2026-03-26 | 17/850 |
|
|
|
[考研] 材料化工340求調(diào)劑 +3 | jhx777 2026-03-30 | 3/150 |
|
|
|
[考研] 303求調(diào)劑 +7 | DLkz1314. 2026-03-30 | 7/350 |
|
|
|
[考研] 求調(diào)劑 +7 | 青春裁為三截 2026-03-29 | 7/350 |
|
|
|
[考研] 070305高分子化學(xué)與物理 304分求調(diào)劑 +12 | c297914 2026-03-28 | 12/600 |
|
|
|
[考研] 本科雙非材料，跨考一志愿華電085801電氣，283求調(diào)劑，任何專業(yè)都可以 +6 | 芝士雪baoo 2026-03-28 | 8/400 |
|
|
|
[考研] 復(fù)試調(diào)劑 +3 | raojunqi0129 2026-03-28 | 3/150 |
|
|
|
[考研] 打過很多競賽，085406控制工程300分，求調(diào)劑 +3 | askeladz 2026-03-26 | 3/150 |
|